Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proteomic contributions to personalized cancer care.
Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS. Koomen JM, et al. Among authors: haura eb. Mol Cell Proteomics. 2008 Oct;7(10):1780-94. doi: 10.1074/mcp.R800002-MCP200. Epub 2008 Jul 29. Mol Cell Proteomics. 2008. PMID: 18664563 Free PMC article. Review.
Smoking relapse-prevention intervention for cancer patients: Study design and baseline data from the surviving SmokeFree randomized controlled trial.
Díaz DB, Brandon TH, Sutton SK, Meltzer LR, Hoehn HJ, Meade CD, Jacobsen PB, McCaffrey JC, Haura EB, Lin HY, Simmons VN. Díaz DB, et al. Among authors: haura eb. Contemp Clin Trials. 2016 Sep;50:84-9. doi: 10.1016/j.cct.2016.07.015. Epub 2016 Jul 25. Contemp Clin Trials. 2016. PMID: 27468664 Free PMC article. Clinical Trial.
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators. Aisner DL, et al. Among authors: haura e. Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7. Clin Cancer Res. 2018. PMID: 29217530 Free PMC article.
Preventing smoking relapse in patients with cancer: A randomized controlled trial.
Simmons VN, Sutton SK, Meltzer LR, Martinez U, Palmer AM, Meade CD, Jacobsen PB, McCaffrey JC, Haura EB, Brandon TH. Simmons VN, et al. Among authors: haura eb. Cancer. 2020 Dec 1;126(23):5165-5172. doi: 10.1002/cncr.33162. Epub 2020 Sep 9. Cancer. 2020. PMID: 32902856 Free PMC article. Clinical Trial.
Gene therapy for lung cancer. An introduction.
Haura EB, Sotomayor E, Antonia SJ. Haura EB, et al. Methods Mol Med. 2003;75:529-43. doi: 10.1385/1-59259-324-0:529. Methods Mol Med. 2003. PMID: 12407762 Review.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
241 results